Prostate cancer with prostate
To Order Contact us: lieven@wlsolutions.be
Prostate cancer tissue array with unmatched normal prostate tissues |
||
| PR481 | each | EUR 198 |
|
Description: Prostate cancer tissue array with unmatched normal prostate tissues, 24 cases/48 cores, with grades, stages and Gleason scores |
||
Prostate cancer with adjacent normal prostate tissue array (2016 WHO classification) |
||
| PR243c | each | EUR 66 |
|
Description: Prostate cancer with adjacent normal prostate tissue array (2016 WHO classification), including pathology grade, TNM, clinical stage, Gleason grade and Gleason score, 12 cases/24 cores, replaced by PR243d |
||
Prostate cancer |
||
| PR632 | each | EUR 306 |
|
Description: Prostate cancer, hyperplasia with normal tissue array, including pathology grade, Gleason grade, Gleason score, TNM and clinical stage, 21cases/63 cores |
||
Prostate cancer tissue array with cancer adjacent tissues |
||
| PR721 | each | EUR 306 |
|
Description: Prostate cancer tissue array with cancer adjacent tissues, including WHO grade, gleason grade, gleason score, TNM and stage info, 24 cases/72 cores |
||
Prostate Cancer Exosome |
||
| P141-PR | - | Ask for price |
Prostate Cancer Exosome RNA |
||
| P241-PR | - | Ask for price |
LNCaP Human prostate cancer |
||
| 94A002 | Vial | EUR 375.07 |
prostate cancer Tissue block |
||
| 97 | 1 unit | EUR 625 |
Prostate cancer tissue array |
||
| BC19021a | each | EUR 306 |
|
Description: Prostate cancer tissue array, with adjacent tissue and normal tissue, including TNM and pathology grade, 28 cases/72 cores, replacing BC19021 |
||
Prostate Cancer Tissue block |
||
| 56 | 1 unit | Ask for price |
Prostate cancer Tissue block |
||
| 73 | 1 unit | EUR 465 |
Prostate cancer tissue array |
||
| PR1001 | each | EUR 306 |
|
Description: Prostate cancer tissue array, including WHO pathology grade and gleason grade, 25 cases/100 cores |
||
Prostate cancer tissue array |
||
| PR483d | each | EUR 198 |
|
Description: Prostate cancer tissue array, including TNM, clinical stage and pathology grade, with Gleason score and WHO grade, 48 cases/48 cores, replacing PR483c |
||
Prostate cancer tissue array |
||
| PR484a | each | EUR 138 |
|
Description: Prostate cancer tissue array, including WHO standerd grade, Gleason grade, Gleason score, TNM and clinical stage, 24 cases/48 cores (core size 1.5mm), replacing PR484 |
||
Prostate cancer tissue array |
||
| PR633a | each | EUR 306 |
|
Description: Prostate cancer tissue array, including TNM, clinical stage and pathology grade, 63 cases/63 cores, replacing PR633 |
||
Prostate cancer with adjacent normal tissue and normal tissue array |
||
| PR1921c | each | EUR 594 |
|
Description: Prostate cancer with adjacent normal tissue and normal tissue array, including pathology grade, Gleason grade, Gleason score, TNM and clinical stage, PSA Marker result, 96 cases/192 cores, (core size 1.0 mm), replacing PR1921b |
||
Cancer of the prostate with progressive changes, 48 cases (1.5mm) |
||
| PRC961 | 1 | EUR 354 |
|
Description: Prostate cancer tissue array, 48 cases from hyperplastic and cancer tissues with progressive Gleason scores and TNM stages in duplicates. |
||
Prostate cancer test tissue array |
||
| T195d | each | EUR 66 |
|
Description: Prostate cancer test tissue array, including TNM, Gleason score and pathology grade, 12 cases/24 cores, replaced by T195e |
||
Prostate Cancer Serum, Human Donor |
||
| MBS170265-INQUIRE | INQUIRE | Ask for price |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS439972-002mgWithBSAAzideat02mgmL | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS439972-01mgWithBSAAzideat02mgmL | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS439972-01mgWithoutBSAAzideat1mgmL | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS439972-5x01mgWithBSAAzideat02mgmL | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS439972-5x01mgWithoutBSAAzideat1mgmL | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS439974-01mL | 0.1mL | EUR 230 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS439974-05mL | 0.5mL | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS439974-5x01mL | 5x0.1mL | EUR 925 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380561-002mgWithBSAAzideat02mgmL | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380561-01mgWithBSAAzideat02mgmL | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380561-01mgWithoutBSAAzideat1mgmL | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380561-5x01mgWithBSAAzideat02mgmL | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380561-5x01mgWithoutBSAAzideat1mgmL | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380562-002mgWithBSAAzideat02mgmL | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380562-01mgWithBSAAzideat02mgmL | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380562-01mgWithoutBSAAzideat1mgmL | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380562-5x01mgWithBSAAzideat02mgmL | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380562-5x01mgWithoutBSAAzideat1mgmL | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380913-002mgWithBSAAzideat02mgmL | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380913-01mgWithBSAAzideat02mgmL | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380913-01mgWithoutBSAAzideat1mgmL | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380913-5x01mgWithBSAAzideat02mgmL | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4380913-5x01mgWithoutBSAAzideat1mgmL | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381589-002mgWithBSAAzideat02mgmL | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381589-01mgWithBSAAzideat02mgmL | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381589-01mgWithoutBSAAzideat1mgmL | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381589-5x01mgWithBSAAzideat02mgmL | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381589-5x01mgWithoutBSAAzideat1mgmL | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381719-002mgWithBSAAzideat02mgmL | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381719-01mgWithBSAAzideat02mgmL | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381719-01mgWithoutBSAAzideat1mgmL | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381719-5x01mgWithBSAAzideat02mgmL | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
AMACR/p504S (Prostate Cancer Marker) |
||
| MBS4381719-5x01mgWithoutBSAAzideat1mgmL | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
LNCaP Human prostate cancer - Premium |
||
| 94AP02 | Vial | EUR 535.82 |
Human Prostate Cancer Primer Library |
||
| HPRC-I | 1 set | EUR 657.6 |
Plasma - Human Prostate Cancer Patient |
||
| MBS170226-INQUIRE | INQUIRE | Ask for price |
LNCaP Human prostate cancer - Corporate |
||
| 94C002 | Vial | EUR 803.73 |
Cancer of the prostate, 102 cases (1.5mm) |
||
| PRC1021 | 1 | EUR 354 |
|
Description: Prostate cancer tissue array, 102 cases of normal/benign (7 cases) and cancer (95 cases with grading and TNM staging data) tissues |
||
Polyclonal AMACR / p504S (Prostate Cancer Marker) Antibody - With BSA and Azide |
||
| APR07208G | 0.05mg | EUR 475.2 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human AMACR / p504S (Prostate Cancer Marker) - With BSA and Azide. This antibody is tested and proven to work in the following applications: |
||
E006AA Human Prostate Cancer Cell Line |
||
| ABI-TC008D | 1 vial | Ask for price |
|
Description: E006AA is a spontaneously Immortalised cell line derived from a Gleason 6 localized prostate cancer in a hormone-naive prostate cancer patient of African American descent. This cell line grows equally well when xenografted into either intact or castrated male NOG-SCID mice and is non-tumorigenic in nude mice. E006AA should be used in parallel with E006AA-ht for modeling the early stages of prostate cancer. |
||
Single Donor Human Prostate Cancer Serum |
||
| ISERSPSTC | each | EUR 209 |
|
Description: Single Donor Human Prostate Cancer Serum |
||
Single Donor Human Prostate Cancer Serum |
||
| MBS8421626-INQUIRE | INQUIRE | Ask for price |
Single Donor Human Prostate Cancer Plasma |
||
| IPLASPSTC | each | EUR 209 |
|
Description: Single Donor Human Prostate Cancer Plasma |
||
Single Donor Human Prostate Cancer Plasma |
||
| MBS8421082-INQUIRE | INQUIRE | Ask for price |
High-density prostate cancer tissue array |
||
| PR208a | each | EUR 546 |
|
Description: High-density prostate cancer tissue array, including TNM, pathology grade and Gleason score, 64 cases/192 cores, replacing PR208 |
||
AMACR / p504S Antibody (Prostate Cancer Marker) |
||
| R32468 | 100 ug | EUR 356.15 |
|
Description: Alpha-methylacyl-CoA racemase (AMACR) is a mitochondrial and peroxisomal enzyme. It encodes a racemase. The encoded enzyme interconverts pristanoyl-CoA and C27-bile acylCoAs between their (R)- and (S)-stereoisomers. The conversion to the (S)-stereoisomers is necessary for degradation of these substrates by peroxisomal beta-oxidation. Encoded proteins from this locus localize to both mitochondria and peroxisomes. Mutations in this gene may be associated with adult-onset sensorimotor neuropathy, pigmentary retinopathy, and adrenomyeloneuropathy due to defects in bile acid synthesis. Alternatively spliced transcript variants have been described. Read-through transcription also exists between this gene and the upstream neighboring C1QTNF3 (C1q and tumor necrosis factor related protein 3) gene. |
||